Investigational Drug Information for Tesetaxel
✉ Email this page to a colleague
What is the development status for investigational drug Tesetaxel?
Tesetaxel is an investigational drug.
There have been 16 clinical trials for Tesetaxel.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2017.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Stomach Neoplasms. The leading clinical trial sponsors are Genta Incorporated, Odonate Therapeutics, Inc., and M.D. Anderson Cancer Center.
There are three hundred and seventy US patents protecting this investigational drug and zero international patents.
Summary for Tesetaxel
| US Patents | 370 |
| International Patents | 4,594 |
| US Patent Applications | 1,063 |
| WIPO Patent Applications | 775 |
| Japanese Patent Applications | 415 |
| Clinical Trial Progress | Phase 2 (2017-12-21) |
| Vendors | 15 |
Recent Clinical Trials for Tesetaxel
| Title | Sponsor | Phase |
|---|---|---|
| The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | Odonate Therapeutics, Inc. | Phase 1 |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | Odonate Therapeutics, Inc. | Phase 2 |
| Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC | Odonate Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for Tesetaxel
Top disease conditions for Tesetaxel
Top clinical trial sponsors for Tesetaxel
US Patents for Tesetaxel
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tesetaxel | ⤷ Sign Up | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Sign Up |
| Tesetaxel | ⤷ Sign Up | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| Tesetaxel | ⤷ Sign Up | Method of reducing blood glucose by administering RON agonists | GENENTECH, INC. (South San Francisco, CA) | ⤷ Sign Up |
| Tesetaxel | ⤷ Sign Up | Glutaminase inhibitors and method of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| Tesetaxel | ⤷ Sign Up | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tesetaxel
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tesetaxel | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Sign Up |
| Tesetaxel | Australia | AU2015231053 | 2034-03-21 | ⤷ Sign Up |
| Tesetaxel | Brazil | BR112016021620 | 2034-03-21 | ⤷ Sign Up |
| Tesetaxel | Canada | CA2943339 | 2034-03-21 | ⤷ Sign Up |
| Tesetaxel | China | CN106231900 | 2034-03-21 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
